Anacetrapib: A New Weapon Against Dyslipidemia

Author(s): Georgios Aperis, Christos Paliouras, Eirini Tsampikaki, Nikolaos Papakonstantinou, Polichronis Alivanis

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 6 , Issue 4 , 2011


Become EABM
Become Reviewer
Call for Editor

Abstract:

Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.

Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 4
Year: 2011
Page: [227 - 235]
Pages: 9
DOI: 10.2174/157488411798375949
Price: $65

Article Metrics

PDF: 16